An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 420-425

  Chen, Taiping ^a   Jackson, Chad ^a   Costello, Ben ^a   Singer, Natalie ^a   Colligan, Bruce ^a   Douglass, Larry ^a   Pemberton, Jackson ^b   Deddens, James ^c   Graff, Jeremy R ^d   Carter, Julia H ^a  

^a Wood Hudson Cancer Research Laboratory   (United States)

^b St Elizabeth Medical Center   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder transitional cell carcinoma; Genetic variant; Renal cell carcinoma; SSCP; TGF type 1 receptor; Upper urinary tract transitional cell carcinoma

Indexed keywords

PHENYLALANINE; SERINE; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLADDER CARCINOMA; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INTRON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

ACTIVIN RECEPTORS, TYPE I; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; FEMALE; HOMOZYGOTE; HUMANS; INTRONS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VARIATION (GENETICS);

EID: 6344283033     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20419     Document Type: Article

References (34)

1. Jemal A, C TR, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001;92:1475-83.
3. Ramp U, Jaquet K, Reinecke P, Kitsch T, Gabbert HE, Gerharz CD. Acquisition of TGF-beta1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 1997;76:739-49.
4. Reiss M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncol Res 1997;9:447-57.
5. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
6. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
7. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9.
8. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer 1988;57:594-600.
9. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540.
10. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996; 7:93-102.
11. Cardillo MR, Lazzereschi D, Gandini O, Di Silverio F, Colletta G. Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma. Anal Quant Cytol Histol 2001;23:109-17.
12. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumorsuppressive pathways in pancreatic carcinoma. Cancer Res 1997;57: 1731-4.
13. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-52.
14. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-4.
15. Kim SK, Fan Y, Papadimitrakopoulou V, dayman G, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996;56:2519-21.
16. Ramp U, Jaquet K, Reinecke P, Schardt C, Friebe U, Kitsch T, Marx N, Gabbert HE, Gerharz CD. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 1997;157:2345-50.
17. Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998;58:4805-10.
18. Chen T, de Vries EG, Hollema H, Yegen HA, Vellucci VF, Strickler HD, Hildesheim A, Reiss M. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer 1999;82:43-51.
19. Chen T, Yan W, Wells RG, Rimm DL, McNiff J, Leffell D, Reiss M. Novel inactivating mutations of transforming growth factor-β type I receptor gene in head-and-neck cancer metastases. Int J Cancer 2001;93:653-61.
20. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J, Graff JR, Carter JH. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001;61:4679-82.
21. Chen T, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Aldaz CM. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 1996;39:177-85.
22. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM. "Cold SSCP:" a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 1993;21:3637-42.
23. Junker U, Knoefel B, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 1996;8:794-8.
24. Wunderlich H, Steiner T, Kosmehl H, Junker U, Reinhold D, Reichelt O, Zermann DH, Schubert J. Increased transforming growth factor betal plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998;60:205-7.
25. Kundu SD, Kim IY, Zelner D, Janulis L, Goodwin S, Engel JD, Lee C. Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca. J Urol 1998;160:1883-8.
26. Miyajima A, Asano T, Seta K, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 2003;61:1072-7.
27. Tokunaga H, Lee DH, Kim IY, Wheeler TM, Lerner SP. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res 1999;5:2520-5.
28. Varley JM, Attwooll C, White G, McGown G, Thorncroft M, Kelsey AM, Greaves M, Boyle S, Birch JM. Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 2001;20:2647-54.
29. Sammarco I, Grimaldi P, Rossi P, Cappa M, Moretti C, Frajese G, Geremia R. Novel point mutation in the splice donor site of exonintron junction 6 of the androgen receptor gene in a patient with partial androgen insensitivity syndrome. J Clin Endocrinol Metab 2000;85:3256-61.
30. Holmila R, Fouquet C, Cadranel J, Zalcman G, Soussi T. Splice mutations in the p53 gene: case report and review of the literature. Hum Mutat 2003;21:101-2.
31. Southey MC, Tesoriero A, Young MA, Holloway AJ, Jenkins MA, Whitty J, Misfud S, kConFab, McLachlan SA, Venter DJ, Armes JE. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. Hum Mutat 2003;22:86-91.
32. Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A, Messiaen L. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 2003;37:314-20.
33. Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VV, et al. Type I transforming growth factor beta receptor maps' to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 1998;58:2727-32.
34. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003;21:3236-43.